Opportunity Information: Apply for RFA MH 13 120
Apply for RFA MH 13 120
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition Genomic Risk and Resilience in 22q11 Deletion Syndrome A Window into the Genetic Architecture of Mental Disorders (Collaborative R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants.
- This funding opportunity was created on Aug 2, 2012 and posted on Aug 2, 2012.
- Applicants must submit their applications by Nov 13, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Funding Opportunity Announcement RFA-MH-13-120, titled "Limited Competition: Genomic Risk and Resilience in 22q11 Deletion Syndrome: A Window into the Genetic Architecture of Mental Disorders (Collaborative R01)," is a National Institute of Mental Health (NIMH) discretionary grant opportunity under the NIH. It supports collaborative R01 research projects focused on genomic analysis using existing biological samples and data that have already been collected from research participants recruited by the International Consortium for 22q11 Deletion Syndrome Research. The central idea is to treat 22q11 Deletion Syndrome (22q DS) as a powerful model system for understanding broader questions in psychiatric genetics, including why certain individuals develop serious neuropsychiatric outcomes while others show relative resilience despite sharing a major genetic risk factor.
The scientific purpose of the FOA is to dissect the genetic architecture underlying brain, behavioral, and neuropsychiatric phenotypes associated with 22q DS. In practical terms, NIMH is looking for studies that can identify additional genomic variants and mechanisms that modify risk among people who already carry the 22q11 deletion. This includes searching for genomic factors that increase vulnerability to outcomes such as psychosis, cognitive impairment, anxiety, mood-related symptoms, or other neurodevelopmental and psychiatric features, as well as factors that appear protective and are linked to better functioning or reduced symptom burden. By concentrating on an existing, consortium-based cohort, the FOA emphasizes leveraging established recruitment, phenotyping, and sample resources to accelerate discovery rather than funding new large-scale sample collection.
This is a limited competition announcement, meaning eligibility is restricted: applications are invited specifically from the International Consortium for 22q11 Deletion Syndrome Research for collaborative R01 awards. The collaborative framing signals that NIMH expects coordinated efforts across investigators or sites, generally reflecting a multi-team structure that can integrate genomic data with rich clinical or neurobehavioral phenotyping already available through the consortium. The work is positioned as relevant not only to 22q DS but also to the broader genetic underpinnings of mental disorders, since understanding modifiers of risk in a high-impact genetic condition can reveal general principles about how multiple genetic factors combine to influence psychiatric outcomes.
From an administrative and funding standpoint, the opportunity is classified under CFDA 93.242 (Mental Health Research Grants). It does not require cost sharing or matching. NIH estimated total funding for the FOA was approximately $3,000,000. The announcement was posted and created on August 2, 2012, with an original and current closing date of November 13, 2012, and an archive date of December 14, 2012, indicating it is no longer open for applications but remains available as a record.
Eligibility details indicate that, in addition to any consortium-specific requirements implied by the limited competition language, non-U.S. (foreign) institutions were eligible to apply, as were non-U.S. components of U.S. organizations. Foreign components, as defined by the NIH Grants Policy Statement, were also allowed. This highlights the international nature of the consortium and the expectation that key expertise, samples, and data may be distributed across multiple countries and institutions.
The administering agency is the National Institutes of Health, specifically NIMH as the issuing institute for this FOA. The full announcement was hosted on the NIH grants website at the provided link. For technical access issues, the FOA listed the NIH Office of Extramural Research (OER) webmaster contact email addresses for support.
Frequently Asked Questions (FAQs)
What is the name and number of this funding opportunity?
The Funding Opportunity Announcement (FOA) is RFA-MH-13-120, titled "Limited Competition: Genomic Risk and Resilience in 22q11 Deletion Syndrome: A Window into the Genetic Architecture of Mental Disorders (Collaborative R01)."
Which agency is offering this opportunity?
This is a National Institutes of Health (NIH) discretionary grant opportunity issued by the National Institute of Mental Health (NIMH).
What type of award mechanism does this FOA use?
The FOA supports Collaborative R01 research projects.
What is the overall scientific goal of this FOA?
The goal is to dissect the genetic architecture underlying brain, behavioral, and neuropsychiatric phenotypes associated with 22q11 Deletion Syndrome (22q DS), using genomic analyses to identify additional variants and mechanisms that modify risk or confer resilience.
Why is 22q11 Deletion Syndrome being used as the focus of this research?
The FOA treats 22q DS as a powerful model system for psychiatric genetics because individuals share a major genetic risk factor (the 22q11 deletion), yet show a wide range of neuropsychiatric outcomes. Studying what modifies vulnerability or resilience in this context is positioned as a way to reveal broader principles relevant to mental disorders.
What kinds of outcomes or phenotypes is NIMH interested in?
The FOA highlights neuropsychiatric and neurodevelopmental outcomes such as psychosis, cognitive impairment, anxiety, mood-related symptoms, and other brain, behavioral, or psychiatric features associated with 22q DS. It also emphasizes identifying protective factors linked to better functioning or reduced symptom burden.
What kind of research approach is expected?
NIMH is looking for genomic analyses that leverage existing biological samples and data already collected from participants recruited by the International Consortium for 22q11 Deletion Syndrome Research, integrating genomic data with rich clinical or neurobehavioral phenotyping available through the consortium.
Does this FOA support new participant recruitment or large-scale new sample collection?
The FOA emphasizes using existing, consortium-based cohorts, samples, and data to accelerate discovery rather than funding new large-scale sample collection.
What does "limited competition" mean for this FOA?
Who is eligible to apply?
Eligibility is restricted to the International Consortium for 22q11 Deletion Syndrome Research under the limited competition language. The FOA also states that non-U.S. (foreign) institutions were eligible to apply, as were non-U.S. components of U.S. organizations, and foreign components as defined by the NIH Grants Policy Statement.
Are foreign institutions and international collaborators allowed?
Yes. The FOA indicates that foreign institutions were eligible, non-U.S. components of U.S. organizations were eligible, and foreign components (per the NIH Grants Policy Statement definition) were allowed, reflecting the international nature of the consortium.
What does "Collaborative R01" imply in this announcement?
The collaborative framing signals that NIMH expects coordinated efforts across investigators or sites, generally reflecting a multi-team structure capable of integrating genomic data with consortium phenotyping and existing sample resources.
What existing resources are applicants expected to use?
The FOA focuses on using existing biological samples and data that have already been collected from research participants recruited by the International Consortium for 22q11 Deletion Syndrome Research, along with the established recruitment and phenotyping infrastructure of the consortium.
How is this research expected to help beyond 22q11 Deletion Syndrome?
The FOA positions the work as relevant to the broader genetic underpinnings of mental disorders, because identifying modifiers of risk and resilience in a high-impact genetic condition can illuminate how multiple genetic factors combine to influence psychiatric outcomes.
What is the CFDA number for this opportunity?
The opportunity is classified under CFDA 93.242 (Mental Health Research Grants).
Is cost sharing or matching required?
No. The FOA states that it does not require cost sharing or matching.
How much total funding was estimated for this FOA?
NIH estimated total funding for the FOA at approximately $3,000,000.
When was the announcement posted, and what were the key dates?
The announcement was posted and created on August 2, 2012. The original and current closing date was November 13, 2012, and the archive date was December 14, 2012.
Is this FOA still open for applications?
No. Based on the listed closing date (November 13, 2012) and archive date (December 14, 2012), it is no longer open for applications and remains available as a record.
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants website at the link provided in the FOA.
Who should be contacted for technical access issues related to the FOA?
For technical access issues, the FOA listed the NIH Office of Extramural Research (OER) webmaster contact email addresses for support.
What is the central research question this FOA is trying to address?
The FOA aims to understand why some individuals with the 22q11 deletion develop serious neuropsychiatric outcomes while others show relative resilience, by identifying additional genomic variants and mechanisms that modify risk or provide protection.
Does the FOA specify that samples and data must come from a particular cohort?
Yes. The FOA specifies a focus on existing biological samples and data already collected from research participants recruited by the International Consortium for 22q11 Deletion Syndrome Research.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Notice of Intent to Award Boston Harbor Islands National Recreation Area youth program
Previous opportunity: Postdoctoral Research Fellowships in Biology
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA MH 13 120
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA MH 13 120) also looked into and applied for these:
| Funding Opportunity |
|---|
| Integrated Maternal, Neonatal, Child Health/Family Planning (MNCHN/FP) Regional Projects in Luzon, Visayas and Mindanao Apply for RFA 492 12 000006 Funding Number: RFA 492 12 000006 Agency: Philippines USAID Manila Category: Health Funding Amount: $27,000,000 |
| Extracellular RNA Biogenesis, Biodistribution, Uptake, and Effector Function (U19) Apply for RFA RM 12 012 Funding Number: RFA RM 12 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Utility of Extracellular RNA for Therapy Development (UH2/UH3) Apply for RFA RM 12 014 Funding Number: RFA RM 12 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Reference Profiles of Human Extracellular RNA (U01) Apply for RFA RM 12 011 Funding Number: RFA RM 12 011 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| Data Management and Resource Repository (DMRR) on Extracellular RNA (U54) Apply for RFA RM 12 010 Funding Number: RFA RM 12 010 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Clinical Utility of Extracellular RNA for Biomarker Development (UH2/UH3) Apply for RFA RM 12 013 Funding Number: RFA RM 12 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Affordable Care Act Teaching Health Center Graduate Medical Education (THCGME) Program Apply for HRSA 13 144 Funding Number: HRSA 13 144 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Estimating the Economic Costs of Alzheimers Disease and Related Dementias (R01) Apply for PA 12 255 Funding Number: PA 12 255 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Estimating the Economic Costs of Alzheimers Disease and Related Dementias (R03) Apply for PA 12 253 Funding Number: PA 12 253 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Estimating the Economic Costs of Alzheimers Disease and Related Dementias (R21) Apply for PA 12 254 Funding Number: PA 12 254 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| National Tuberculosis and Leprosy Control Program (NTLP) Apply for RFA 623 12 000008 Funding Number: RFA 623 12 000008 Agency: Kenya USAID Nairobi Category: Health Funding Amount: $12,500,000 |
| 2013 NIH Directors Pioneer Award Program (DP1) Apply for RFA RM 12 015 Funding Number: RFA RM 12 015 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| 2013 NIH Directors New Innovator Award Program (DP2) Apply for RFA RM 12 016 Funding Number: RFA RM 12 016 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Development and Application of Systems Approaches for Analyzing the Impact of Genomic Variation on Tissue Transcriptomes (R01) Apply for RFA RM 12 019 Funding Number: RFA RM 12 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Grants for Health Services Research Dissertation Program (R36) Apply for PA 12 256 Funding Number: PA 12 256 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| AHRQ Individual Awards for Postdoctoral Fellows (F32) National Research Service Awards (NRSA) Apply for PA 12 261 Funding Number: PA 12 261 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Tribal Self Governance Program Planning Cooperative Agreement Apply for HHS 2012 IHS TSGP 0001 Funding Number: HHS 2012 IHS TSGP 0001 Agency: Indian Health Service Category: Health Funding Amount: $120,000 |
| Limited Competition NIMHD Community Based Participatory Research (CBPR) Initiative in Reducing and Eliminating Health Disparities Dissemination Phase (R24) Apply for RFA MD 13 001 Funding Number: RFA MD 13 001 Agency: National Institutes of Health Category: Health Funding Amount: $375,000 |
| NIMH Short Courses for Mental Health Related Research Education (R25) Apply for PAR 12 262 Funding Number: PAR 12 262 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIMH Research Education Programs Supporting Psychiatric Residents (R25) Apply for PAR 12 263 Funding Number: PAR 12 263 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA MH 13 120", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.